【Good News】Haibu Pharmaceutical's Perindopril and Amlodipine Tablets (Ⅲ) have been accepted by CDE.

Beijing Haibu Pharmaceutical Technology Co., Ltd. (referred to as 'Haibu Pharmaceutical') was established in 2005 and is a high-tech enterprise with 'chemical drug research and development' as its core capability. It has a research and development center in Beijing, an active pharmaceutical ingredient and formulation pilot verification center, and a GMP industrial production base, mainly engaged in CRO services for active pharmaceutical ingredients and formulations, MAH joint licensing, related applications for active pharmaceutical ingredients, and commercial supply of pharmaceutical intermediates.Haibu Pharmaceutical has rich experience in the research and development transfer, registration application, etc., of various dosage forms such as chemical raw materials, oral solids, liquid preparations, sterile injections, external preparations. The R&D products cover multiple therapeutic areas including anti-tumor, anti-depression, anti-epilepsy, anti-anxiety, cardiovascular and cerebrovascular diseases, digestive system diseases, respiratory system diseases.

Haibu Pharmaceutical has been awarded the title of 'Top 20 Chinese Pharmaceutical R&D Companies' for several consecutive years and recognized as a 'Specialized & Innovative Enterprise' in Beijing, a 'National High-tech Enterprise', a 'Beijing Science and Technology Research Development Institution', and a 'Beijing Yizhuang Enterprise Innovation Center'.